

Decision Letter (JCQ-2026-0027)

From:

To:

CC:

BCC:

Subject: Journal of Clinical Question - Decision on Manuscript ID JCQ-2026-0027

Body: 21-Aug-2026

Dear Dr Beleva:

Manuscript ID JCQ-2026-0027 entitled "Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer" which you submitted to the Journal of Clinical Question, has been reviewed. The comments of the reviewer(s) are included at the bottom of this letter.

The reviewer(s) have recommended publication, but also suggest some minor revisions to your manuscript. Therefore, I invite you to respond to the reviewer(s)' comments and revise your manuscript.

To submit your revised manuscript, follow the below steps.

1. Access to <https://mc.manuscriptcentral.com/jcq> and log into the site.
2. Click "Author" at the top left of the screen at "Home" page.
3. Click "Manuscripts with Decisions" on Author Dashboard page.
4. Click "create a revision" on the manuscript you are going to revise.
5. The system creates your revision manuscript form. Provide your comments about the revised points at the response field, fill in on each field step by step as same as you did for the original submission, and submit your revised manuscript.

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Your manuscript number has been appended to denote a revision.

You will be unable to make your revisions on the originally submitted version of the manuscript. Instead, revise your manuscript using a word processing program and save it on your computer. Please also highlight the changes to your manuscript within the document by using the track changes mode in MS Word or by using bold or colored text.

Once the revised manuscript is prepared, you can upload it and submit it through your Author Center.

When submitting your revised manuscript, you will be able to respond to the comments made by the reviewer(s) in the space provided. You can use this space to document any changes you make to the original manuscript. In order to expedite the processing of the revised manuscript, please be as specific as possible in your response to the reviewer(s).

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission.

Because we are trying to facilitate timely publication of manuscripts submitted to the Journal of Clinical Question, your revised manuscript should be uploaded as soon as possible. If it is not possible for you to submit your revision in a reasonable amount of time, we may have to consider your paper as a new submission.

Once again, thank you for submitting your manuscript to the Journal of Clinical Question and I look forward to receiving your revision.

Sincerely,
Richard S. Isaacs
Editor in Chief
Journal of Clinical Question

[Editor's Comments]
Associate Editor
Comments to the Author:
(There are no comments.)

[Reviewer(s)' Comments]
Reviewer: 1

Comments to the Author

Dear Editors, authors of manuscript or to whom it may concern,

I am honored to receive an invitation from the magazine and editor to review the paper submitted to this journal. This article, titled "Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer", provides a good summary and analysis of the hot and difficult issues in the field, while also delving into the solutions and challenges faced by the problem. After carefully reading and analyzing the content, language, logic, and structure of this article by myself, combined with my professional field, I propose the following opinions and suggestions for reference only:

1. Please add consecutive line numbers to facilitate further reading and quick positioning for readers and reviewers.

2. It is suggested that the article include more illustrations and tables to further elaborate on the content, facilitating readers' understanding.

3. At present, is the combination of PD-1 and VEGF feasible for lung squamous cell carcinoma? How do you evaluate the current market of ivonescimab?

We look forward to the early disclosure of relevant clinical research results and hope to further improve and optimize existing clinical diagnosis and treatment strategies.

In summary, I believe that this article has certain reference value and guiding significance for clinical treatment. I also hope that the author could further revise and polish the article based on my opinions and suggestions, so that it can be published as soon as possible.

Finally, I also welcome the author to actively communicate and exchange ideas with me.

Best wishes!

Reviewer: 2

Comments to the Author

The manuscript by Aleena Kuriakose et al. is an excellent and comprehensive review of the implementation of bispecific antibodies in NSCLC. I recommend accepting the manuscript for publication in its current form.

Date Sent: 21-Aug-2026



Print



Close Window

Author's Response to Decision Letter for (JCQ-2026-0027)

Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer

Dear Editor and Reviewers,

We sincerely thank the reviewers for their careful evaluation and constructive comments. The manuscript has been revised accordingly. To facilitate review, all newly added text is shown in red in the revised manuscript, and continuous line numbering is provided throughout.

Reviewer 1

Comment 1 : Please add consecutive line numbers to facilitate further reading and quick positioning for readers and reviewers.

Response: Thank you for this helpful suggestion. Continuous line numbering has been applied throughout the revised manuscript to facilitate review and cross-referencing.

Comment 2 : It is suggested that the article include more illustrations and tables to further elaborate on the content, facilitating readers' understanding.

Response: Thank you for this suggestion. We carefully reviewed the visual presentation of the manuscript. The current version already contains one mechanistic illustration (Figure 1) and four summary tables (Tables 1–4), which together summarize the biological rationale, available clinical evidence, and ongoing clinical development of PD-1/VEGF and PD-L1/VEGF bispecific antibodies. Because an additional figure or table would largely duplicate information already presented in these elements and in the text, we retained the existing visual structure to maintain clarity and avoid redundancy.

Comment 3 : At present, is the combination of PD-1 and VEGF feasible for lung squamous cell carcinoma? How do you evaluate the current market of ivonescimab?

Response: Thank you for raising this clinically important point. The feasibility of combined PD-1/VEGF blockade in squamous NSCLC is now supported by the randomized phase III HARMONi-6 trial, which is already described in the manuscript and demonstrated significant PFS and OS benefit with ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. In addition, in August 2026, the China National Medical Products Administration approved ivonescimab plus chemotherapy for first-line treatment of advanced squamous NSCLC. We therefore added a brief statement to clarify both the feasibility of this strategy in squamous histology and the current regulatory/market position of ivonescimab. We intentionally kept this addition concise to avoid repeating the detailed HARMONi-6 efficacy and safety data already presented in the subsequent Ivonescimab section. (Page 10, lines 167–171)

Reviewer 2

Comment: The manuscript by Aleena Kuriakose et al. is an excellent and comprehensive review of the implementation of bispecific antibodies in NSCLC. I recommend accepting the manuscript for publication in its current form.

Response: We sincerely thank the reviewer for the positive assessment of our manuscript and for recommending acceptance. No additional revisions were requested by Reviewer 2.

We again thank the Editor and Reviewers for their constructive comments, which have helped improve the clarity and clinical relevance of the manuscript.

Elina Beleva

Clinic of Hematology, Military Medical Academy, Sofia, Bulgaria

Tel: +359 2 922 6000

elina.beleva@biomed.bas.bg